{"url_path":"/sec/cik-0001900520/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1900520/0001213900-26-057605-index.html","accession_number":"0001213900-26-057605","cik":"0001900520","ticker":null,"issuer_name":"Lomond Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1900520/0001213900-26-057605-index.html","primary_entity_key":"0001900520","primary_entity_name":"Lomond Therapeutics Holdings, Inc."},"word_count":61,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\nRule 10b5-1 Trading Plans\n\n \n\nDuring the three months ended March 31, 2026,\nnone of our directors or officers entered into, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule\n10b5-1 trading arrangement,” that were intended to satisfy the affirmative defense conditions of Rule 10b5-1, in each case as defined\nin Item 408 of Regulation S-K.\n\n \n\n29"}